Why the study?
Does chlorobutanol inhibit human platelet aggregation and release in vitro?
Does chlorobutanol inhibit human platelet aggregation and release in vitro?
Chlorobutanol, a preservative in parenteral desmopressin, potently inhibits human platelet aggregation in vitro, suggesting it may counteract the hemostatic benefits of desmopressin.
Should not yet alter desmopressin use; animal data leaves open chlorobutanol effects on human platelets.
Therapeutic preparations of desmopressin for parenteral use contain the preservative chlorobutanol (5 mg/ml). We show here that chlorobutanol is a potent inhibitor of platelet aggregation and release. It exhibited a significant inhibitory activity toward several aggregation inducers in a concentration- and time-dependent manner. Thromboxane B2 formation, ATP release, and elevation of cytosolic free calcium caused by collagen, ADP, epinephrine, arachidonic acid and thrombin respectively were markedly inhibited by chlorobutanol. Chlorobutanol had no effect on elastase-treated platelets and its antiplatelet effect could be reversed. It is concluded that the antiplatelet effect of chlorobutanol is mainly due to its inhibition on the arachidonic acid pathway but it is unlikely to have a nonspecific toxic effect. This antiplatelet effect of chlorobutanol suggests that desmopressin, when administered for improving hemostasis, should not contain chlorobutanol as a preservative.
No takes yet. Share an insight, caveat, or question.
Chen et al. (1990) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: